Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo

Tumor Biology

Volumn 36, Issue 11, 2015, Pages 8499-8510

  Yao, Nan ^a   Ren, Ke ^b,c   Jiang, Cuihua ^a   Gao, Meng ^a   Huang, Dejian ^a   Lu, Xiao ^d   Lou, Bin ^a   Peng, Fei ^a   Yang, Aizhen ^d   Wang, Xiaoning ^a   Ni, Yicheng ^a,e   Zhang, Jian ^a  

^a Jiangsu Province Academy of Traditional Chinese Medicine   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d The Jingdu hospital of Nanjing   (China)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Combretastatin A4 phosphate (CA4P); Hypoxia; Tumor regrowth; Vasculogenic mimicry

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; EPHRIN RECEPTOR A2; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE 14; PHOSPHATIDYLINOSITOL 3 KINASE; HIF1A PROTEIN, HUMAN; NITROIMIDAZOLE DERIVATIVE; PIMONIDAZOLE; STILBENE DERIVATIVE;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR VOLUME; VASCULOGENIC MIMICRY; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; CELL HYPOXIA; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MAMMARY NEOPLASMS, ANIMAL; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MAMMARY NEOPLASMS, ANIMAL; NEOVASCULARIZATION, PATHOLOGIC; NITROIMIDAZOLES; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; SIGNAL TRANSDUCTION; STILBENES;

EID: 84949089411     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3508-x     Document Type: Article

References (54)

1. Folberg R, Maniotis AJ. Vasculogenic mimicry. Apmis. 2004;112(7–8):508–25. doi:10.1111/j.1600-0463.
2. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155(3):739–52. doi:10.1016/S0002-9440(10)65173-5.
3. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol. 2012;181(4):1115–25. doi:10.1016/j.ajpath.2012.07.013.
4. Vartanian AA, Stepanova EV, Gutorov SL, Solomko E, Grigorieva IN, Sokolova IN, et al. Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma. Can J Urol. 2009;16(4):4726–32.
5. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001;61(2):445–51.
6. Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Cohen MB, et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate. 2002;50(3):189–201. doi:10.1002/pros.10048.
7. Sun B, Zhang S, Zhao X, Zhang W, Hao X. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol. 2004;25(6):1609–14.
8. Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett. 2007;249(2):188–97. doi:10.1016/j.canlet.2006.08.016.
9. Zhang S, Li M, Zhang D, Xu S, Wang X, Liu Z, et al. Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma. Lab Invest. 2009;89(5):575–86. doi:10.1038/labinvest.
10. Hendrix MJ, Seftor RE, Seftor EA, Gruman LM, Lee LM, Nickoloff BJ, et al. Transendothelial function of human metastatic melanoma cells role of the microenvironment in cell-fate determination. Cancer Res. 2002;62(3):665–8.
11. Jain RK, Carmeliet P. SnapShot: tumor angiogenesis. Cell. 2012;149(6):1408-.e1. doi:10.1016/j.cell.2012.05.025.
12. Moserle L, Casanovas O. Anti-angiogenesis and metastasis: a tumour and stromal cell alliance. J Intern Med. 2013;273(2):128–37. doi:10.1111/joim.12018.
13. Xu Y, Li Q, Li X, Yang Q, Xu W, Liu G. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. 2012;31(1):16. doi:10.1186/1756-9966-31-16.
14. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med. 2007;85(12):1301–7. doi:10.1007/s00109-007-0281-3.
15. Semenza GL. Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets. 2006;10(2):267–80. doi:10.1517/14728222.10.2.267.
16. Ma J, Han S, Zhu Q, Zhao J, Zhang D, Wang L, et al. Role of twist in vasculogenic mimicry formation in hypoxic hepatocellular carcinoma cells in vitro. Biochem Biophys Res Commun. 2011;408(4):686–91. doi:10.1016/j.bbrc.2011.04.089.
17. Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, et al. A review on various targeted anticancer therapies. Target Oncol. 2012;7(1):69–85. doi:10.1007/s11523-012-0212-2.
18. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev. 2011;37(1):63–74. doi:10.1016/j.ctrv.2010.05.001.
19. Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, et al. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol. 2009;44(1):44–53. doi:10.1097/RLI.0b013e31818e5ace.
20. Li J, Chen F, Feng Y, Cona MM, Yu J, Verbruggen A, et al. Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology. Transl Oncol. 2013;6(1):42–50. doi:10.1593/tlo.12367.
21. Milanović D, Braun F, Weber W, Grosu AL, Behe M, Niedermann G. The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts. BMC Cancer. 2012;12(1):242. doi:10.1186/1471-2407-12-242.
22. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005;5(6):423–35. doi:10.1038/nrc1628.
23. Siemann DW, Chaplin DJ, Horsman MR. Vascular‐targeting therapies for treatment of malignant disease. Cancer. 2004;100(12):2491–9. doi:10.1002/cncr.20299.
24. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66(24):11520–39. doi:10.1158/0008-5472.CAN-06-2848.
25. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5(7):516–25. doi:10.1038/nrc1650.
26. Zweifel M, Jayson GC, Reed N, Osborne R, Hassan B, Ledermann J, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol. 2011;22(9):2036–41. doi:10.1093/annonc/mdq708.
27. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62(12):3408–16.
28. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001;61(17):6413–22.
29. Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys. 1998;42(4):895–8. doi:10.1016/S0360-3016(98)00299-5.
30. Zhao D, Jiang L, Hahn EW, Mason RP. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys. 2005;62(3):872–80. doi:10.1016/j.ijrobp.2005.03.009.
31. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation role of epithelial cell kinase (Eck/EphA2). Cancer Res. 2001;61(8):3250–5.
32. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 2002;83(1):21–38. doi:10.1046/j.1365-2613.2002.00211.x.
33. Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol. 2002;21(4):717–26. doi:10.3892/ijo.21.4.717.
34. Ljungkvist AS, Bussink J, Rijken PF, Kaanders JH, van der Kogel AJ, Denekamp J. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2002;54(1):215–28. doi:10.1016/S0360-3016(02)02938-3.
35. Bussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol. 2003;67(1):3–15. doi:10.1016/S0167-8140(03)00011-2.
36. Kovacs EM, Ali RG, McCormack AJ. E-cadherin homophilic ligation directly signals through Rac and phosphatidylinositol 3-kinase to regulate adhesive contacts. J Biol Chem. 2002;277(8):6708–18. doi:10.1074/jbc.M109640200.
37. El-Emir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Begent RH, et al. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer. 2005;41(5):799–806. doi:10.1016/j.ejca.2005.01.001.
38. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008;28(4B):2027–31.
39. Taylor M, Billiot F, Marty V, Rouffiac V, Cohen P, Tournay E, et al. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov. 2012;2(5):434–49. doi:10.1158/2159-8290.CD-11-0171.
40. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest. 2011;121(5):1969–73. doi:10.1172/JCI44562.
41. Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res. 2009;69(19):7524–8. doi:10.1158/0008-5472.CAN-09-0381.
42. van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Oude Egbrink MG, et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. 2005;65(24):11520–8. doi:10.1158/0008-5472.CAN-05-2468.
43. Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys. 2002;54(5):1491–6. doi:10.1016/S0360-3016(02)03924-X.
44. Li J, Sun Z, Zhang J, Shao H, Miranda Cona M, Wang H, et al. A dual-targeting anticancer approach: soil and seed principle. Radiology. 2011;260(3):799–807. doi:10.1148/radiol.11102120.
45. Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol. 2001;158(4):1279–88. doi:10.1016/S0002-9440(10)64079-5.
46. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59(22):5830–5.
47. Maxwell P, Dachs G, Gleadle J, Nicholls L, Harris A, Stratford I, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1997;94(15):8104–9.
48. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol. 2000;59(1):47–53. doi:10.1016/S0006-2952(99)00292-0.
49. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res. 2012;18(10):2726–32. doi:10.1158/1078-0432.CCR-11-3237.
50. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta. 2010;1806(1):18–28. doi:10.1016/j.bbcan.2010.01.001.
51. Hess AR, Seftor EA, Seftor RE, Hendrix MJ. Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 2003;63(16):4757–62.
52. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997;277(5323):225–8. doi:10.1126/science.277.5323.225.
53. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol. 2000;148(3):615–24. doi:10.1083/jcb.148.3.615.
54. Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, et al. Cooperative interactions of laminin 5 γ2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 2001;61(17):6322–7.